Merck Q1 2026 Performance: Growth and Innovatio...

By HEOR Staff Writer

April 30, 2026

Merck’s first-quarter 2026 results have been published and highlight key growth drivers, regulatory achievements, and strategic moves that reinforce the company’s diversified portfolio. Oncology Dominance Fueled by KEYTRUDA Expansion
Advancing High-Risk Oncology Interventions: Promising Developments from ASCO ...
Establishing a Vaccine Confidence Strategy: EMA’s New Advisory Group Ta...
Advancing Supply Chain Resilience in Europe’s Off-Patent Medicines Sector
Advancing Subcutaneous Diuretic Therapy for Heart Failure Management
TikTok Opioid Overdose Forecasting: Leveraging Social Media Data for Enhanced...
Enhancing Breakthrough Medical Device Access: EMA’s New Pilot Program f...
Medical Device Innovation South Africa: Breaking Down Systemic Barriers
Expanding Access to Hormonal IUDs in South Africa through Generic Innovation
Regulatory Divergence in PSMA Targeted Therapy: Implications for European Mar...
PIONEER TEENS Trial Reveals Oral Semaglutide Diabetes Breakthrough for Pediat...
Terminal Complement Inhibition: Promising Results in IgAN from the I CAN Trial
Advancing Multicenter AKI Prediction: Benefits of Collaborative Models Over L...